Ante-mortem Diagnostics for Prion Infection
朊病毒感染的生前诊断
基本信息
- 批准号:7670946
- 负责人:
- 金额:$ 17.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-03-13 至 2010-09-12
- 项目状态:已结题
- 来源:
- 关键词:AchievementAcuteAnimalsAntibodiesAntidotesAppearanceArchivesBacillus anthracisBiologicalBiological AssayBloodBlood specimenBovine Spongiform EncephalopathyBrainCaliberCattleCenters for Disease Control and Prevention (U.S.)ChemistryClinicalClinics and HospitalsCopperDetectionDevelopmentDiagnosisDiagnosticDiagnostic ProcedureDiseaseEarly DiagnosisEatingElectrodesEndopeptidase KEnzyme-Linked Immunosorbent AssayEquipmentExhibitsFoodGenerationsGoalsGoldHarvestHourHumanHuman ResourcesIgG1ImmunohistochemistryIncinerationIndustryInfectionInjection of therapeutic agentLifeLiquid substanceMarketingMedicineMethodsMicroelectrodesMicrofluidicsMicroscopeModelingMole the mammalMonitorMusNeurologic DysfunctionsOpticsOrganismPatientsPharmaceutical PreparationsPhasePhase I Clinical TrialsPrPSc ProteinsPreparationPrion DiseasesPrionsProcessPumpReadingReagentResearchResistanceSamplingScrapieSerumSheepSignal TransductionSilverSodium HypochloriteSolutionsSourceStagingSymptomsSyringesSystemTechnologyTestingTherapeuticTimeTissuesTitaniumTonsilTrainingUnited StatesUnited States National Institutes of HealthUrineVaccinesWestern BlottingWorkbeefbiosafety level 2 facilitycostdesigndetectordrug efficacyhazardinstrumentlymph nodesmeetingsminiaturizepreventprogramspublic health relevanceresearch studysealtoolwasting
项目摘要
DESCRIPTION (provided by applicant): Vegrandis proposes to develop a rapid, sensitive, high throughput, inexpensive, and easy to use system for the ante-mortem diagnosis of prion infection. The proposed system offers a fully automated equipment with a disposable microelectrochemical cartridge for diagnosis of ante- mortem levels as low as 1 x 10-15 molar (possibly 1 x 10-21molar) concentrations of PrPSc in a rapid assay at d 30 min, high throughput allowing > 100 samples/h per fully automated instrument, high sensitivity with > 95% reliability (eliminating false positives and false negatives), and with minimal potential hazard of handling patient biological fluid. Unlike existing diagnostic methods of prion infection which are usable only when patients already show acute signs of neurologic dysfunctions and are provisional until post-mortem tissue homogenate diagnosis rules out or confirms the diagnosis, the proposed system is anticipated to diagnose asymptomatic stage prion infection that can be used for at least three important purposes: 1) eliminate contaminated animals and animal products from entering the market; 2) use in developing and monitoring the efficacy of drugs, vaccine, or other therapeutic molecules that are being developed; and 3) monitor changes in the PrPSc levels during medication. The proposed system will eliminate the use of post mortem tissue homogenates for diagnosis by allowing asymptomatic and ante-mortem diagnosis through the use of self-contained microelectro- chemistry in 50-micron diameter wells in a disposable cartridge (DC) format. The sample will be injected into the self-sealing inlet port on the DC, the DC will be inserted into the fully automated instrument, the reagents will be placed in the reagent module, and the proper program will be chosen. The instrument read out will display the concentration of PrPSc at the end of <30 min. During Phase I, Vegrandis will demonstrate the technology proof-of-concept by performing experiments using scrapie as the model analyte. Phase I is anticipated to:1) detect as low as femtomolar levels of PrPSc, 2) <45 min assay from capture to signal generation, 3) non- interference of debris from biological samples eliminating tedious sample preparation steps, and 4) low assay cost resulting from the use of small reagent volumes (d 10 <L for the entire microarray or ~0.5 <L per microwell). Achievement of the milestones in Phase I will advance the research to Phase II where we envision to a) develop a miniaturized flow injection instrument a high throughput fully automated detection of asymptomatic prion infection, b) achieve 1 x 10-21 molar PrPSc detection, and c) develop a 100-channel pico-ampere electrochemical analyzer for 100 sample analysis per hour total assay time. The same instruments and disposable cartridge will have use in stationary or mobile clinics or hospitals as a diagnostic tool for the early detection, ante- and post-mortem detection of prion disease. As additional details about prions and their antibodies become available, they will be incorporated into the disposable cartridge for further study. PUBLIC HEALTH RELEVANCE: Millions of cows are slaughtered annually for food in the United States. After the discovery of the first domestic case of mad cow disease in 2004, national US beef industry losses were recorded at $3.2 to $4.7 billion for that year alone. People have died worldwide from prion infection resulting from eating infected beef. Ante-mortem detection of prion infection will prevent the spread of this fatal disease that currently has no vaccine, antidote, or medicine to cure. Therefore, avoiding contamination is essential. Development of a fully automated, portable instrument that uses compact, disposable cartridges and requires no pre-analysis sample preparation for ante-mortem prion infection is proposed. Preliminary work indicates that the proposed approach will be able to meet the high sensitivity required to diagnose the asymptomatic stage of this fatal disease.
描述(由申请人提供):Vegrandis提出开发一种快速、灵敏、高通量、廉价且易于使用的系统,用于朊病毒感染的生前诊断。所提出的系统提供了一个全自动化的设备与一次性微电化学盒的诊断生前水平低至1 × 10-15摩尔(可能为1 × 10- 21摩尔)浓度的PrPSc在第30分钟的快速测定中,高通量允许每个全自动仪器> 100个样品/h,高灵敏度,可靠性> 95%(消除假阳性和假阴性),处理患者生物液体的潜在危险最小。与现有的朊病毒感染诊断方法不同,现有的朊病毒感染诊断方法仅在患者已经显示出神经功能障碍的急性体征时才可用,并且在死后组织匀浆诊断排除或确认诊断之前是临时的,所提出的系统预期诊断无症状阶段的朊病毒感染,其可用于至少三个重要目的:1)消除被污染的动物和动物产品进入市场; 2)用于开发和监测正在开发的药物、疫苗或其他治疗分子的功效;和3)监测药物治疗期间PrPSc水平的变化。所提出的系统将通过在一次性盒(DC)格式的50微米直径威尔斯孔中使用自含式微电化学进行无症状和生前诊断,从而消除使用死后组织匀浆进行诊断。将样品注入DC上的自密封入口端口,将DC插入全自动仪器,将试剂放置在试剂模块中,并选择适当的程序。仪器读数将在<30分钟结束时显示PrPSc的浓度。在第一阶段,Vegrandis将通过使用羊瘙痒病作为模型分析物进行实验来证明技术概念验证。阶段I预期:1)检测低至飞摩尔水平的PrPSc,2)从捕获到信号产生<45分钟的测定,3)来自生物样品的碎片的非干扰,消除了繁琐的样品制备步骤,以及4)由于使用小试剂体积(对于整个微阵列d10 <L或每个微孔约0.5 <L)而导致的低测定成本。第一阶段里程碑的实现将把研究推进到第二阶段,在第二阶段,我们设想a)开发一种小型化流动注射仪器,用于无症状朊病毒感染的高通量全自动检测,B)实现1 x 10-21摩尔PrPSc检测,以及c)开发一种100通道皮安电化学分析仪,用于每小时100个样品分析的总测定时间。相同的仪器和一次性检测盒将用于固定或移动的诊所或医院,作为早期检测、死前和死后检测朊病毒疾病的诊断工具。随着关于朊病毒及其抗体的更多细节的获得,它们将被纳入一次性检测盒中以供进一步研究。公共卫生相关性:在美国,每年有数百万头牛被屠宰作为食物。在2004年发现第一例国内疯牛病病例后,仅在那一年,美国全国牛肉行业的损失就达到了32亿至47亿美元。全世界都有人因食用受感染的牛肉而死于朊病毒感染。死前检测朊病毒感染将防止这种目前没有疫苗、解毒剂或药物可治愈的致命疾病的传播。因此,避免污染至关重要。开发一种全自动,便携式仪器,使用紧凑,一次性盒,不需要分析前的样本制备的死前朊病毒感染的建议。初步工作表明,所提出的方法将能够满足诊断这种致命疾病的无症状阶段所需的高灵敏度。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chamika Wansapura其他文献
Chamika Wansapura的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chamika Wansapura', 18)}}的其他基金
Carbon Nanopipette Cellular Probe for Microinjections into Mammalian Cells
用于哺乳动物细胞显微注射的碳纳米移液器细胞探针
- 批准号:
7804891 - 财政年份:2010
- 资助金额:
$ 17.47万 - 项目类别:
Carbon Nanopipette ElectroProbe in Cell-Electrophysiology Applications
碳纳米移液器电探针在细胞电生理学应用中的应用
- 批准号:
7746216 - 财政年份:2009
- 资助金额:
$ 17.47万 - 项目类别:
Magnetohydrodynamic-based Laboratories on a Chip
基于磁流体动力学的芯片实验室
- 批准号:
7125149 - 财政年份:2003
- 资助金额:
$ 17.47万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 17.47万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 17.47万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 17.47万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 17.47万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 17.47万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 17.47万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 17.47万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 17.47万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 17.47万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 17.47万 - 项目类别:
Operating Grants